BETHESDA, Md., Jan. 9, 2014 /PRNewswire/ -- Northwest
Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a
biotechnology company developing non-toxic DCVax® personalized
immune therapies for cancer, announced today that Linda Powers, CEO, will present at the Biotech
Showcase™ 2014 Conference that is being held in San Francisco from January 13-15, 2014.
(Logo:
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)
NW Bio's presentation will take place on Monday, January 13, at 4:00 p.m. PST in the Mission II Room at the
Parc55 Hotel Wyndham, 55 Cyril Magnin St, Union Square. There
will be a live audio webcast of the presentation available at
http://nwbio.com/webcasts/. During her presentation, Ms.
Powers will provide an overview of the Company's cancer vaccine
platform technology, product pipeline and clinical programs
with DCVax-L and DCVax-Direct.
If you are interested in meeting with NW Bio's management during
the conference, please contact Lisa
Sher of MBS Value Partners at Lisa.Sher@mbsvalue.com.
About Northwest Biotherapeutics
Northwest Biotherapeutics is developing cancer vaccines designed
to treat a broad range of solid tumor cancers more effectively than
current treatments, and without the side effects of chemotherapy
drugs. NW Bio's proprietary manufacturing technology enables
the Company to produce its personalized vaccine in an efficient,
cost-effective manner. The Company has a broad platform
technology for DCVax dendritic cell-based vaccines. The
Company's lead product, DCVax-L, is currently in a 312-patient
Phase III trial in the U.S. and Europe for patients with newly diagnosed
Glioblastoma multiforme (GBM), the most aggressive and lethal brain
cancer. The Company's second product, DCVax-Direct, is
currently in a 60-patient Phase I/II trial for direct injection
into all types of inoperable solid tumor cancers. The Company
has also conducted a small Phase I/II trial with DCVax for
metastatic ovarian cancer together with the University of Pennsylvania. The Company
previously received clearance from the FDA for a 612-patient Phase
III trial with its third product, DCVax-Prostate, for late stage
prostate cancer.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "plan," "continue," "may," "will," "anticipate," and
similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those
projected in any forward-looking statement. Specifically,
there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the
Company's ability to raise additional capital, risks related to the
Company's ability to enroll patient s in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company's products will
demonstrate safety and efficacy. Additional information on
these and other factors, including Risk Factors, which could affect
the Company's results, is included in its Securities and Exchange
Commission ("SEC") filings. Finally, there may be other
factors not mentioned above or included in the Company's SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement. You should not
place undue reliance on any forward-looking statements. The
Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.